<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937183</url>
  </required_header>
  <id_info>
    <org_study_id>MSCMI-40-2003</org_study_id>
    <secondary_id>CDR0000636859</secondary_id>
    <secondary_id>EU-20913</secondary_id>
    <nct_id>NCT00937183</nct_id>
  </id_info>
  <brief_title>Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma</brief_title>
  <official_title>Vaccination of Lymphoma Patients With Dendritic Cell-lymphoma Cell Hybrids and Dendritic Cells Pulsed With Tumor Lysates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as a dendritic cell vaccine made with a patient's
      cancer cells, may stimulate the immune system in different ways and stop cancer cells from
      growing.

      PURPOSE: This phase I/II trial is studying the side effects of dendritic cell vaccine and to
      see how well it works in treating patients with indolent B-cell lymphoma or multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluation of feasibility of dendritic cell (DC)-based vaccination program using
           autologous tumor cells and/or lysates in patients with indolent B cell lymphomas or
           multiple myeloma as an adjuvant therapy to induce immune response in remission after
           cytoreductive treatment.

        -  Evaluation of the immune response of patients treated with this regimen.

        -  Evaluation the progression-free survival of patients treated this regimen.

        -  Evaluate the adverse events of this regimen in these patients.

      OUTLINE: Patients receive intranodal (under ultrasound guidance) or subcutaneous vaccinations
      of adjuvant electrofusion hybrids of autologous dendritic cells (DC) with autologous lymphoma
      cells, electrofusion hybrids of allogeneic DC with autologous lymphoma cells, and/or
      autologous DC pulsed with autologous tumor lysate cells in weeks 0, 2, 4, 8, 12, 18, 26, and
      50.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Mantle cell lymphoma

               -  Marginal zone lymphoma

               -  Follicular lymphoma

               -  Small lymphocytic lymphoma/chronic lymphocytic leukemia

               -  Multiple myeloma

               -  Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia

               -  Diffuse large B-cell lymphoma

          -  Adequate sample size and lymphoma cell content in the fresh tissue collected

          -  No bulky or progressive disease

        PATIENT CHARACTERISTICS:

          -  Life expectancy &gt; 3 months

          -  No evidence of lung, heart, liver, or renal failure or severe neurologic disorder

          -  No autoimmune disease or atopic allergy

          -  No HIV positivity

          -  No other malignancy

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Walewski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maria Sklodowska-Curie Institute - Oncology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Walewski, MD</last_name>
      <phone>48-22-546-2223</phone>
      <email>walewski@coi.waw.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage II grade 1 follicular lymphoma</keyword>
  <keyword>stage II grade 2 follicular lymphoma</keyword>
  <keyword>stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage II small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage II marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage II mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

